Last reviewed · How we verify
NCT06307288
Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea
Phase 4 trial testing minocycline in Rosacea in 45 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | Second Affiliated Hospital of Xi'an Jiaotong University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 16 October 2023 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- minocycline (MINOCYCLINE) — full drug profile →
- tranilast — full drug profile →
Conditions studied
- Rosacea — all drugs for Rosacea →
Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Who can join
Adults 18 to 60, any sex, with Rosacea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rosacea is a chronic inflammatory skin disease with a complex pathogenesis involving multiple factors. Currently, the treatment of rosacea remains highly challenging. Mast cells, as key participants in the pathogenesis of rosacea, have been shown to alleviate rosacea symptoms with some topical, oral, and injectable mast cell stabilizers in recent years. Tranilast stabilizes mast cells and basophils by acting on their cell membranes and preventing their degranulation. Tranilast has been used in the treatment of various skin disease, such as hypertrophic scars and atopic dermatitis. Minocycline is a first-line treatment for rosacea, and low-dose minocycline treatment (50mg/day) is believed to have anti-inflammatory effects without antibacterial effects, thus minimizing the dysbiosis and bacterial resistance caused by antibiotic use. Therefore, this study aims to investigate the effectiveness and safety of combining mast cell stabilizer tranilast with low-dose minocycline treatment for rosacea, providing new treatment options and insights for rosacea patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148
Verify or expand the search:
- PubMed search for NCT06307288
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of minocycline
Trials testing the same drug.
- NCT05958069 — The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients · NA · unknown
- NCT05474729 — Minocycline for Chronic Autoimmune Uveitis · Phase 1, PHASE2 · recruiting
- NCT05474950 — Minocycline Treatment for Cystoid Macular Edema · Phase 1, PHASE2 · unknown
Other recruiting trials for Rosacea
Currently open trials in the same condition.
- NCT07296497 — Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety · NA · recruiting
- NCT06312813 — Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With · Phase 2 · recruiting
- NCT06072066 — Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammatio · NA · recruiting
- NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
- NCT05928169 — Determinants of Chronic Inflammatory Skin Disease Trajectories · recruiting
Other Second Affiliated Hospital of Xi'an Jiaotong University trials
Trials by the same sponsor.
- NCT07160361 — Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB · Phase 4 · not yet recruiting
- NCT07346456 — Comparison of IOL Formulas in Eyes With PCE≥15µm · completed
- NCT06998589 — Comparison of the Efficacy and Safety of Delicate Pulsed Light and Q-Switched 1064 nm Nd:YAG Laser in the Treatment of P · NA · completed
- NCT07305675 — Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment · NA · completed
- NCT06791005 — A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06307288 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Xi'an Jiaotong University
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06307288.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing